Clinical Trials Logo

Cocaine-Related Disorders clinical trials

View clinical trials related to Cocaine-Related Disorders.

Filter by:

NCT ID: NCT04907357 Not yet recruiting - Cocaine Dependence Clinical Trials

rTMS for Stimulant Use Disorders

CTN-0108
Start date: August 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to determine feasibility of repetitive transcranial magnetic stimulation (rTMS) for individuals with moderate to severe cocaine or methamphetamine use disorder (CUD/MUD). Potential participants will be age 18-65, and interested in cutting down or stopping use. Participants will be randomized to one of two groups; groups will receive rTMS or sham rTMS (placebo) over the course of an 8-week treatment period, and complete follow-up assessments at the end of treatment, 12, and 16 weeks post-randomization.

NCT ID: NCT04884594 Not yet recruiting - Clinical trials for Cocaine Dependence, in Remission

AAV8-hCocH for Cocaine Use Disorder

Start date: September 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of a novel gene viral vector treatment for adults with cocaine use disorder-sustained remission. This gene regulates an enzyme (cocaine hydrolase) that breaks down cocaine into inactive substances, thereby decreasing the pleasurable feeling this drug usually provides.

NCT ID: NCT04411914 Recruiting - Cocaine Dependence Clinical Trials

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

Start date: September 1, 2020
Phase: Phase 1
Study type: Interventional

A dose-escalation study to determine the optimum dose of CLAV for effects on craving and efficacy.

NCT ID: NCT04336293 Not yet recruiting - Cocaine Addiction Clinical Trials

sTMS for Substance Use-disordered Veterans

Start date: May 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if synchronized transcranial magnetic stimulation is safe and tolerable in individuals with cocaine, opioid, or alcohol use disorders.

NCT ID: NCT04306354 Recruiting - Clinical trials for Cocaine-Related Disorders

Use of Intranasal Oxytocin During Detoxification of Crack Cocaine

Start date: September 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized treatment control trial, double-blind, parallel, with two arms including ninety-six hospitalized women between 18 and 52 years. Those who agree to participate in the study and meet the eligibility criteria will be randomly allocated to one of the following experimental conditions: - Conventional oxytocin treatment (T + OC): 32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization. - Conventional treatment with placebo administration (T + PBO): 32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization. - Conventional treatment (T): 32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization. Outcomes: Withdrawal symptoms, Anxiety symptoms and Depressive symptoms

NCT ID: NCT04280900 Not yet recruiting - Clinical trials for Cocaine-Related Disorders

Benefits of Therapy With Virtual Reality Exposure in the Treatment of Cocaine Use Disorders

CORVI
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Cocaine addiction is a multifactorial disease with important consequences: somatic, psychiatric... The number of applications for treatment for cocaine addiction is gradually increasing from year to year but no conventional treatment is available. New tools such as virtual reality could be used in this treatment. We propose to create a virtual reality program based on the analysis of high-risk relapse situations described by patients. We will then assess the effect of this cybertherapy on patients' relapse time and their desire to use cocaine

NCT ID: NCT04155632 Recruiting - Clinical trials for Cocaine-Related Disorders

Neurocircuit Strategy to Decrease Cocaine Cue Reactivity

COCA
Start date: December 18, 2020
Phase: Phase 2
Study type: Interventional

The overarching goal of this project is to examine the effect of combining theta burst stimulation (TBS) and N-acetylcysteine (NAC) on cocaine craving and brain response to cocaine-related images.

NCT ID: NCT03986762 Completed - Clinical trials for Cocaine-Related Disorders

Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid

CLAVMRPilot
Start date: March 12, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine how the study drug, clavulanic acid, affects glutamate in the brain using Magnetic Resonance (MR/MRI) scans. In this study, subjects will receive the study drug, clavulanic acid and undergo 4 MRI scans. This is being studied to determine the correct dosing of clavulanic acid, and to gather data so future studies can be done to find out if this drug is helpful in treating cocaine dependence. Currently, there is no available medication treatment for cocaine dependence.

NCT ID: NCT03971097 Completed - Clinical trials for Alcohol Use Disorder

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, & Maguen, 2018) and the Substance Abuse Self-Stigma Scale (SASSS) (Luoma et al., 2013). Data will be collected from two groups of participants receiving counseling at the short-term rehabilitation facility located at University of Pittsburgh Medical Center's (UPMC). Individuals who agree to participate in the study will be randomly assigned to either the experimental group (EG) or the control group (CG). Data collected will include pre-test SFDPS and SASSS scores for the EG and the CG (collected within 24-hours of admission), and post-test SFDPS and SASSS scores for the EG and CG (collected after 14 days). ANCOVA will be used to analyze the pre-test and post-test data recorded from participants' scores.

NCT ID: NCT03953612 Recruiting - Clinical trials for Cocaine-Related Disorders

The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders

Start date: March 12, 2019
Phase: Early Phase 1
Study type: Interventional

To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the role of neuroactive steroids in individuals with cocaine use disorder (CUD).